BRWD3 Antibody

What is the biological function of BRWD3 that makes it an important research target?

BRWD3 plays a significant role in epigenetic regulation through multiple mechanisms. It binds directly to H3K4 methylation through a cryptic Tudor domain and to acetylated histones via its bromodomains . More importantly, BRWD3 functions as a substrate receptor for the Cul4 E3 ubiquitin ligase complex and regulates H3K4 methylation levels by promoting the ubiquitination and degradation of KDM5, an H3K4-specific lysine demethylase . This regulation is critical for maintaining proper H3K4 methylation status, which is linked to active gene transcription. Loss of BRWD3 function results in altered H3K4 methylation patterns, particularly affecting H3K4me3 levels throughout the genome .

How do I select the appropriate anti-BRWD3 antibody for my research?

Selection of an appropriate anti-BRWD3 antibody depends on several factors:

• Experimental application: Confirm the antibody has been validated for your specific application (WB, IHC, ICC, IF, ELISA) .

• Species reactivity: Verify the antibody recognizes BRWD3 in your model organism. Commercial antibodies are typically validated for human and mouse samples .

• Epitope recognition: Consider the immunogen sequence. For example, some antibodies target a peptide derived from human BRWD3 at amino acids 1751-1800 .

• Validation data: Review available validation images and experimental data to ensure the antibody demonstrates specificity and sensitivity in contexts similar to your research design .

For cross-species applications not explicitly listed in the specifications, pilot experiments are recommended to validate cross-reactivity .

What are the recommended protocols for using anti-BRWD3 antibodies in ChIP-seq experiments?

When designing ChIP-seq experiments with anti-BRWD3 antibodies, researchers should consider the following methodological approaches:

• Cross-linking optimization: Given BRWD3's role as a chromatin-binding protein, standard formaldehyde cross-linking (1% for 10 minutes) is typically sufficient, but optimization may be required.

• Spike-in normalization: For accurate quantification of binding, include spike-in controls such as SNAP synthetic nucleosomes (EpiCypher) for normalization. This is particularly important when comparing BRWD3 binding across different conditions .

• Sonication parameters: Target DNA fragments of 200-500bp for optimal resolution of BRWD3 binding sites.

• Antibody validation: Perform preliminary ChIP-qPCR at known BRWD3 binding sites to verify antibody efficiency before proceeding to sequencing .

• Data analysis: When analyzing BRWD3 ChIP-seq data, compare the observed overlap with histone modifications (particularly H3K4me3, H3K27ac, H3K9ac, and H3K18ac) which are significantly enriched at BRWD3 binding sites .

Results interpretation should consider that approximately 50% of BRWD3 binding sites overlap with KDM5 sites genome-wide, reflecting their functional interaction .

How can I effectively use anti-BRWD3 antibodies for immunoprecipitation studies?

For optimal immunoprecipitation (IP) studies with anti-BRWD3 antibodies:

• Sample preparation: Use Benzonase-digested extracts to remove DNA/RNA that might interfere with protein-protein interactions .

• IP conditions:

  • Buffer composition: PBS containing protease inhibitors and minimal detergent (0.1% NP-40 or Triton X-100)

  • Antibody amounts: 2-5 μg per 500 μg of protein lysate

  • Incubation: Overnight at 4°C with gentle rotation

• Protein complex detection: For identification of BRWD3-interacting proteins, consider coupling IP with quantitative mass spectrometry using techniques like tandem mass tags (TMT) labeling .

• Controls: Include appropriate negative controls (non-immune IgG) and positive controls (known BRWD3 interactors such as Cul4, Pic/DDB1, and Roc1A) .

• Validation: Confirm interactions through reciprocal co-IP or proximity ligation assays.

This approach has successfully identified interactions between BRWD3 and the H3K4-specific lysine demethylase KDM5/Lid, as well as components of the Cul4 E3 ubiquitin ligase complex .

How can I investigate the role of BRWD3 in regulating KDM5 stability and activity?

To study BRWD3's regulation of KDM5 stability and activity, consider these methodological approaches:

• Ubiquitination assays: To assess KDM5 ubiquitination dependency on BRWD3:

  • Develop a system with tagged KDM5 and ubiquitin

  • Perform immunoprecipitation under denaturing conditions

  • Compare ubiquitination patterns with and without BRWD3 depletion

  • Western blot analysis with anti-ubiquitin antibodies, focusing on K48-linked polyubiquitination

• Protein stability measurements: Implement cycloheximide (CHX) chase assays to measure KDM5 half-life in the presence and absence of BRWD3:

  • Treat cells with CHX to inhibit new protein synthesis

  • Collect samples at different time points

  • Analyze KDM5 protein levels by western blot

• Functional rescue experiments: To establish causality:

  • Deplete BRWD3 and observe H3K4me3 level reduction

  • Simultaneously deplete KDM5 to determine if this rescores normal H3K4me3 levels

  • Quantify H3K4 methylation patterns using ChIP-seq with spike-in normalization

• Structure-function analysis: Generate BRWD3 constructs with mutations in domains critical for interaction with the Cul4 complex to determine which regions are essential for KDM5 regulation.

These approaches collectively provide mechanistic insight into how BRWD3 regulates KDM5 activity and subsequently affects H3K4 methylation patterns .

What methods can be used to study the genomic co-localization of BRWD3 and KDM5?

To investigate the genomic co-localization of BRWD3 and KDM5, researchers should consider the following methodological approaches:

• Sequential ChIP (Re-ChIP): This technique can determine if BRWD3 and KDM5 bind simultaneously to the same DNA fragments:

  • Perform initial ChIP with anti-BRWD3 antibody

  • Elute complexes and perform second ChIP with anti-KDM5 antibody

  • Analyze enriched regions by qPCR or sequencing

• Comparative ChIP-seq analysis:

  • Generate high-quality ChIP-seq datasets for both BRWD3 and KDM5 from the same cell type/tissue

  • Use statistical methods to calculate both the enrichment and significance of peak overlaps

  • Compare observed overlap with expected overlap from randomly shuffled sets of peaks

  • Consider using the following statistical parameters: P-value = 0.001, log2-fold change > 2.0 to define significant co-localization

• Integration with histone modification data:

  • Compare BRWD3 and KDM5 binding sites with H3K4me1/2/3 marks

  • Research has shown H3K4me3 is significantly enriched at BRWD3 binding sites (log2-fold change = 3.48)

  • Analyze whether changes in BRWD3 occupancy affect local KDM5 binding and vice versa

This analytical framework can reveal that approximately 50% of BRWD3 binding sites overlap with KDM5 sites throughout the genome, providing insight into their functional relationship in regulating H3K4 methylation .

How can I optimize anti-BRWD3 antibody specificity for immunohistochemistry applications?

To optimize anti-BRWD3 antibody specificity for immunohistochemistry:

• Antigen retrieval optimization:

  • Test multiple antigen retrieval methods (heat-induced epitope retrieval with citrate buffer pH 6.0, EDTA buffer pH 9.0, or enzymatic retrieval)

  • Optimize retrieval time (10-30 minutes) and temperature

• Antibody concentration titration:

  • Begin with manufacturer's recommended dilution range (1/100 - 1/300)

  • Prepare a dilution series and identify optimal signal-to-noise ratio

  • Consider longer incubation times (overnight at 4°C) for more dilute antibody solutions

• Blocking optimization:

  • Test different blocking solutions (BSA, normal serum, commercial blockers)

  • Extend blocking time (1-2 hours) to reduce background

• Signal amplification:

  • For tissues with low BRWD3 expression, consider using polymer-based detection systems or tyramide signal amplification

• Specificity controls:

  • Include tissue from BRWD3 knockdown models

  • Perform peptide competition assays using the immunogen peptide (amino acids 1751-1800)

Researchers have reported successful IHC applications with anti-BRWD3 antibodies in human cervix carcinoma tissues, demonstrating the feasibility of these approaches across various tissue types .

What are the best approaches for troubleshooting unexpected cross-reactivity with anti-BRWD3 antibodies?

When confronting unexpected cross-reactivity issues with anti-BRWD3 antibodies:

• Sequence homology analysis:

  • Compare BRWD3 sequences across species to identify regions of high conservation

  • For unconventional model organisms like zebrafish, perform in silico analysis of the immunogen sequence (e.g., amino acids 1751-1800) against the target species proteome

  • Consider homology with other BRWD family members (BRWD1, BRWD2) that might cross-react

• Validation experiment design:

  • Use positive and negative control tissues/cell lines with known BRWD3 expression levels

  • Include BRWD3-knockdown or knockout samples as specificity controls

  • Perform western blot analysis to identify potential cross-reactive bands based on molecular weight

• Epitope masking assessment:

  • Test different fixation protocols that might affect epitope accessibility

  • Adjust detergent concentrations in blocking and antibody diluent solutions

• Alternative antibody evaluation:

  • Test antibodies raised against different BRWD3 epitopes

  • Consider monoclonal antibodies for higher specificity if polyclonal antibodies show cross-reactivity

These approaches allow researchers to adapt their experimental design when working with nonstandard model organisms or when investigating specific BRWD3 isotypes .

How should I interpret changes in BRWD3 binding patterns in relation to histone modifications?

When analyzing changes in BRWD3 binding patterns in relation to histone modifications:

• Prioritize modification relationships: Research shows BRWD3 binding sites are most significantly enriched for H3K4me3 (P value = 0.001, log2-fold change = 3.48), followed by lower enrichment for H3K4me2 and H3K4me1. This mirrors the in vitro binding affinity of the BRWD3 cryptic Tudor domain for these marks .

• Consider acetylation marks: BRWD3 binding sites also show enrichment for H3K27ac, H3K9ac, and H3K18ac, consistent with the BRWD3 bromodomain binding to these modifications in combination with H3K4 methylation .

• Analyze binding site distributions: When examining genomic distributions:

  • Assess enrichment at promoters versus enhancers

  • Evaluate BRWD3's association with transcriptionally active regions

  • Consider the co-localization with KDM5 (~50% overlap)

• Interpret dynamic changes: When analyzing changes in response to experimental perturbations:

  • Determine if BRWD3 binding precedes or follows changes in histone modifications

  • Assess whether loss of BRWD3 function results in local or global changes in H3K4 methylation patterns

  • Evaluate if BRWD3 depletion causes uniform reduction in H3K4me3 ChIP-seq reads at peak regions

• Statistical analysis framework:

  • Compare observed overlaps with expected overlaps from randomly shuffled sets of peaks

  • Calculate both enrichment values and statistical significance

  • Use spike-in normalization for accurate quantitative comparisons

This analytical framework helps establish the functional relationship between BRWD3 binding and its role in maintaining proper H3K4 methylation status.

What experimental approaches can help resolve contradictory findings regarding BRWD3's effects on H3K4 methylation levels?

To address contradictory findings regarding BRWD3's effects on H3K4 methylation:

• Standardized quantification methods:

  • Implement spike-in normalization for ChIP-seq experiments using synthetic nucleosomes (e.g., EpiCypher SNAP system)

  • Perform parallel western blot, immunofluorescence, and ChIP-qPCR analyses to confirm findings across multiple methodologies

  • Use absolute quantification approaches rather than relative comparisons

• Context-dependent regulation assessment:

  • Analyze BRWD3 effects across different cell types or developmental stages

  • Compare acute versus chronic BRWD3 depletion to distinguish direct from compensatory effects

  • Consider the balance between methyltransferase and demethylase activities in different systems

• Mechanistic dissection:

  • Perform epistasis experiments depleting both BRWD3 and KDM5 to determine if KDM5 degradation is the primary mechanism

  • Evaluate whether KDM5 degradation is dependent on both BRWD3 and Cul4

  • Test if depleting KDM5 restores altered H3K4me3 levels upon BRWD3 depletion

• Temporal dynamics analysis:

  • Use time-course experiments after BRWD3 depletion to distinguish primary from secondary effects

  • Implement rapid protein degradation systems (e.g., auxin-inducible degron) for acute BRWD3 removal

• Domain-specific functionality:

  • Generate BRWD3 constructs with mutations in specific domains (Tudor domain, bromodomains, CRL substrate-receptor domains)

  • Determine which domains are essential for regulation of different H3K4 methylation states

These approaches can reconcile apparently contradictory findings, such as observations that BRWD3 loss increases H3K4me1 in some systems while affecting H3K4me3 in others .